VALIDATED RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF CEFIXIME AND MOXIFLOXACIN IN COMBINED PHARMACEUTICAL DOSAGE FORM

Objective: To develop a simple, selective and rapid reversed phase high performance liquid chromatographic (HPLC) method for the analysis of cefixime and moxifloxacin in combined pharmaceutical dosage form as per ICH guidelines.Methods: The separation was achieved from C18 column at 350C with a mobile phase consisting of methanol: 0.05M heptane sulfonic acid sodium salt,0.5 ml THF and 0.5 ml TEA [75: 25 v/v]. pH-3.8 was adjusted with ortho phosphoric acid at a flow rate of 0.4 ml/min and the retention time was about 6.08 minutes for cefixime and 6.94 minutes for moxifloxacin. The method was selective to cefixime and moxifloxacin able to resolve the drug peak from formulation excipients.Results: The calibration curve was linear over the concentration range of 20-120 μg/ml (r2 = 0.999) for both drugs. The proposed method was found to be accurate and precise and linear within the desired range. The limit of detection (LOD) and limit of quantitation (LOQ)were calculated statically. Recoveries do not differ significantly from 100% which show there was no interference from the common excipient used in tablet formulation indicating accuracy and reliability of the method. The method was validated as per ICH guidelines and found to be accurate, precise and rugged. The method was validated in terms of linearity, accuracy, precision, specificity, LOD and LOQ.Conclusion: A novel, simple, selective and rapid reversed phase high performance liquid chromatographic (HPLC) method was developed for the analysis of cefixime and moxifloxacin in tablets. Hence,the method can be used for the routine analysis in various pharmaceutical industries.Â

Development and Validation of Stability Indicating RP-HPLC Method for Estimation of Rilpivirine Hydrochloride in Tablet Dosage Form

A simple, sensitive, rapid and reproducible HPLC Method was developed and validated for estimation of Rilpivirine in the presence of degradation products generated from forced decomposition studies. The analysis was carried out on Hypersil BDS C18, 250 X 4.6mm, 5? column using a mixture of ammonium acetate Buffer (pH to 6.0 0.05) and Acetonitrile in the proportion 55:45 respectively as a mobile phase at a flow rate of 1.2 mL/minute. The wavelength selected for the analysis was 300 nm. The peak for Rilpivirine HCl was observed at 10.33 minute. A linear response was observed in the range of 12.5 - 62.5 ?g/mL with a correlation coefficient of 0.999. The method was validated for specificity, linearity, precision, accuracy and robustness. The obtained results were indicating that the method is selective in analysis of Rilpivirine in the presence of degradation products formed under various stress conditions

CRYSTAL ENGINEERING OF ANTIVIRAL AGENT EFAVIRENZ FOR SOLUBILITY ENHANCEMENT

In the current study, we attempted to improve the physicochemical properties of antiviral drug efavirenz through the cocrystal synthesis. The neat grinding performed to study the effect of coformer-fumaric acid (FA) on solubility and dissolution of efavirenz, which can serve as the green cocrystal synthesis approach. The prepared cocrystals were characterized for characteristics like powder flow properties, aqueous saturation solubility, in vitro powder dissolution study. The synthesized cocrystals were characterized by Fourier transform infrared spectroscopy, differential scanning calorimetry, powder X-ray diffraction. The formation of a cocrystal of efavirenz and caffeine was confirmed by the characterization techniques which suggests the interactions between efavirenz and coformer-fumaric acid leads to cocrystal formation. The powder flow properties, solubility, and dissolution profile of efavirenz are significantly improved by its cocrystallization.Â

Antifungals: Need to Search for a New Molecular Target

In the 1990s, drug resistance has become an important problem in a variety of infectious diseases including human immunodeficiency virus infection, tuberculosis, and other bacterial infections which have profound effects on human health. At the same time, there have been dramatic increase in the incidence of fungal infections, which are probably the result of alterations in immune status associated with the acquired immuno deficiency syndrome epidemic, cancer chemotherapy, and organ and bone marrow transplantation. The rise in the incidence of fungal infections has exacerbated the need for the next generation of antifungal agents, since many of the currently available drugs have undesirable side effects, are ineffective against new or reemerging fungi, or lead to the rapid development of the resistance. This review will focus on the pathogenic yeast Candida albicans, since a large body of work on the factors and mechanism associated with antifungal drug resistance in this organism is reported sufficiently. It will certainly elaborate the probable molecular targets for drug design, discovered to date

Antioxidant, antimicrobial activity and in silico PASS prediction of Annona reticulata Linn. root extract

Microbial infections and diseases are frequently associated with several pathogenic strains of bacteria and fungi. Plants of the reticulata genus are a notable source of new therapeutic agents including antioxidant and antimicrobial. This study reports the antioxidant and antimicrobial activities of methanolic root extract of Annona reticulata Linn. The antioxidant property of extract was evaluated using DPPH free radical scavenging and hydrogen peroxide assay. Antibacterial tests were performed using the agar cup method whereas Poison plate method was used to assess sensitivity of fungal strains. The biological potential of major phytoconstituents as antimicrobial agent was screened by new software based tool, PASS. The dose dependent scavenging was observed at concentrations 20, 40, 60, 80 and 100 μg/ml which were compared to ascorbic acid. The probable activity (Pa) of neoannonin using PASS was found to be 0.541. The extract was significantly active against all strains of bacteria but the largest zone of inhibition was found against B. cereus. Predominant growth reduction was observed in fungi Tricoderma viride and Candida albicans. The results indicate that the extract show potential as a source of new antimicrobial drug and may impart health benefits by its antioxidant property

RECENT RESEARCH ON ANALYTICAL METHODS OF ANALYSIS OF RALTEGRAVIR AND ELVITEGRAVIR : A REVIEW

ABSTRACT Highly Active antiretroviral therapy ( HAART ), a combination drug therapy is a topic of current interest in the treatment of HIV and AIDS. Techniques for the analysis and the quality control of antiretroviral drugs, particularly in the drug combinations are vital in achieving quality of these drugs and the treatments involved. Integrase inhibitor are a class of antiretroviral drug designed to block the action of integrase , a viral enzymes that inserts a viral genome into the DNA of the host cell. Since integration is a vital step in retroviral replication, blocking it can halt further spread of the virus. Integrase inhibitor were initially developed for the treatment of HIV infection . The HPLC,UV and HPTLC methods are available for the analysis of Raltegravir and Elvitegravir, the recently used drug for HIV and AIDS are reviewed in this articles

Improving decision making for drug candidates: A computational approach for benzthiazoles as antifungal

389-396To improve the decision making for selecting a molecule for synthesis from a set of virtually designed antifungal compounds, four in silico approaches are discussed and their optimization have been confirmed by in vitro methods. First, a set of compounds was designed over QSAR analysis and selected over predicted activities by best QSAR equation (r2>0.9) to increase the probability of finding new chemical entities. To reduce the burden of synthetic chemistry, Rule of Five was applied for screening druggable compounds. Second, OSIRIS was used to predict toxicity, mutagenicity and carcinogenicity. Third approach was prediction of biological activity spectra for substances (PASS) and fourth was molecular docking to analyze the actual interaction involved after binding with the target receptor. All compounds of the series passed rule of five. On the basis of OSIRIS prediction results, nine compounds were selected. PASS predictions have resulted into suitability of only one compound (test 30) as antifungal. Molecular docking at BioMed CAChe workstation was then performed for this compound. Comparison of active site residues at receptor binding and dock score with fluconazole has further confirmed the compound for synthesis. The synthesized compound has given MIC 16 µg/mL at antifungal assay against Candida albicans by potato dextrose agar method. It confirmed that in silico approaches are useful to find out a new drug with more accuracy